Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Frumovitz

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
Gynecologic Oncology|December 4, 2012
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignanciesKathleen M Schmeler, Ginger L Wilson, Katherine Cain, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 9, 2020
Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital chargesKatherine I Stewart, Jarrod S Eska, Ross F Harrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2024
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical CancerPedro T Ramirez, Kristy P Robledo, Michael Frumovitz, et al.
Journal of Oncology Practice|October 16, 2019
Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology CenterDonna S Zhukovsky, Pamela T Soliman, Boby Mathew, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 17, 2024
Molecular image-guided surgery in gynaecological cancer: where do we stand?Giusi Pisano, Thomas Wendler, Renato A Valdés Olmos, et al.
American Journal of Obstetrics and Gynecology|March 12, 2023
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumorsKatherine I Foster, Alejandra Flores Legarreta, Rhea Kamat, et al.
Oncotarget|June 14, 2019
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy optionsMarilyne Labrie, Tae-Beom Kim, Zhenlin Ju, et al.
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Endocrine-Related Cancer|May 15, 2023
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasmsJennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2016
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 CasesPriyadharsini Nagarajan, Jonathan L Curry, Jing Ning, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
Gynecologic Oncology|December 4, 2012
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignanciesKathleen M Schmeler, Ginger L Wilson, Katherine Cain, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 9, 2020
Implementation of a sentinel lymph node mapping algorithm for endometrial cancer: surgical outcomes and hospital chargesKatherine I Stewart, Jarrod S Eska, Ross F Harrison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2024
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical CancerPedro T Ramirez, Kristy P Robledo, Michael Frumovitz, et al.
Journal of Oncology Practice|October 16, 2019
Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology CenterDonna S Zhukovsky, Pamela T Soliman, Boby Mathew, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 17, 2024
Molecular image-guided surgery in gynaecological cancer: where do we stand?Giusi Pisano, Thomas Wendler, Renato A Valdés Olmos, et al.
American Journal of Obstetrics and Gynecology|March 12, 2023
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumorsKatherine I Foster, Alejandra Flores Legarreta, Rhea Kamat, et al.
Oncotarget|June 14, 2019
Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy optionsMarilyne Labrie, Tae-Beom Kim, Zhenlin Ju, et al.
Gynecologic Oncology Reports|January 15, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008)Alessandro D Santin, Virginia Filiaci, Stefania Bellone, et al.
Endocrine-Related Cancer|May 15, 2023
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasmsJennifer R Eads, Thorvardur R Halfdanarson, Tim Asmis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2016
Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 CasesPriyadharsini Nagarajan, Jonathan L Curry, Jing Ning, et al.
Pageof 23